AADI - Aadi Bioscience, Inc.
IEX Last Trade
3.03
-0.030 -0.990%
Share volume: 2,408
Last Updated: Thu 26 Dec 2024 08:29:03 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$3.06
-0.03
-0.98%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
4.90%
1 Month
29.87%
3 Months
57.07%
6 Months
87.50%
1 Year
49.25%
2 Year
-76.04%
Key data
Stock price
$3.03
DAY RANGE
$2.96 - $3.08
52 WEEK RANGE
$1.41 - $3.60
52 WEEK CHANGE
$42.86
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO: Neil P. Desai
Region: US
Website: aadibio.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: aadibio.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin.
Recent news